KR20150050906A - Antibiotic composition - Google Patents
Antibiotic composition Download PDFInfo
- Publication number
- KR20150050906A KR20150050906A KR1020130132136A KR20130132136A KR20150050906A KR 20150050906 A KR20150050906 A KR 20150050906A KR 1020130132136 A KR1020130132136 A KR 1020130132136A KR 20130132136 A KR20130132136 A KR 20130132136A KR 20150050906 A KR20150050906 A KR 20150050906A
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- present
- antimicrobial
- composition
- antimicrobial composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식물 정유를 포함하는 항균제 조성물에 관한 것이다. 특히 본 발명은 병원성 곰팡이의 생육을 저해하는 회향유,계피유,페파민트유로 군으로부터 선택된 항균성 조성물에 관한 것이다.The present invention relates to an antimicrobial composition comprising a plant essential oil. In particular, the present invention relates to an antimicrobial composition selected from the group consisting of fennel oil, cinnamon oil, and peppermint oil channel inhibiting the growth of pathogenic fungi.
진균(곰팡이)에 의해 발생되는 발생되는 피부질환을 총칭하여 피부진균증(derma-tomycosis)이라 한다. 특히 피부의 각질, 모발, 손톱, 발톱 등의 각질조직에 침입하여 기생하는 피부사상균(dermatophyte)에 의해 발생되는 경우를 피부사상균증(derma-tophytosis), 백선(Tinea) 또는 표재성진균증(superficial fungal infection)이라고 한다.(Ribbon, J. W.(1998) Medical Mycology. In The pathogenic fungi and the pathogenic actinomyces. 2nd Ed. W.B.Saunders Comoany. Philadelphia, London, toronto.)Skin diseases caused by fungi (fungus) are collectively referred to as derma-tomycosis. (Dermatophyte), Tinea or Superficial fungal infection, which is caused by parasitic dermatophyte penetrating into keratin tissues such as keratin, hairs, nails and claws of skin, (Ribbon, JW (1998) Medical Mycology. In The pathogenic fungi and the pathogenic actinomyces., 2nd ed. WBSaunders Comoany. Philadelphia, London, toronto.)
표재성진균증은 피부 침입부위에 따라 발생부위가 손과 발인 경우 수족족부백선(Tinea manus Tinea pedis), 얼굴인 경우 안면부백선(Tinea faciale), 두부의 경우에는 두부백선(Tinea capitis), 서혜부(사타구니)에 발생했을 때에는 완선(Tinea crusis), 손톱과 발톱의 경우에는 조갑백선(Tinea ungium 또는 Onychomy-cosis), 상기 부위를 제외한 곳에 발생한 경우를 체부백선(Tinea corporis)이라고 부른다.(Rezab다, G.H. and Friedman, A.D. 1992. Drugs 43(5): 674-682. : Kamalam, A. and Thambiah, A.S. 1976. Sabouraudia 14(2): 129-148).In case of superficial fungus, Tinea manus Tinea pedis in case of hands and feet, Tinea faciale in case of face, Tinea capitis in case of tofu, Tinea crusis in case of nails and toenails, Tinea ungium or Onychomy-cosis in case of nails and claws, and Tinea corporis in cases where it is excluded. (Rezab da GH and Friedman, AD 1992. Drugs 43 (5): 674-682.: Kamalam, A. and Thambiah, AS 1976. Sabouraudia 14 (2): 129-148).
표재성 진균증의 주된 원인은 소아포균(microsporum), 표피균(epidermo-phyton), 백색균(Trichophyton), 칸디다균(candida species), 이다. 특히 백색균은 피부, 체모, 조갑 모두를 침입할 수 있는 특성을 가지고 있다.(Weitzman, I. and Summerbell, R.C. 1995. The dermatophytes. Clinical Microbiology Rewiews 8(2): 240-259)The main causes of superficial mycoses are microsporum, epidermo-phyton, Trichophyton, and candida species. In particular, white fungi have the property of invading both skin, hair, and nail (Weitzman, I. and Summerbell, R.C. 1995. The dermatophytes. Clinical Microbiology Rewiews 8 (2): 240-259)
표재성 진균증의 원인균들은 상피세포 상부의 각질조직(keratin)에 기생히여 번식함으로써 표재성 병변을 유발하지만, 때때로 상피 상부이하까지도 염증을 유발할 수도 있고, 백선진(Dermatophytid)을 일으키기도 한다.The causative organisms of superficial fungi are parasitic on the keratin of the upper part of the epithelium and cause superficial lesions. Sometimes, they may cause inflammation even below the epithelium and cause dermatophytidosis.
병원성 곰팡이는 전 세계적으로 분포하며, 사람을 포함한 동물에 질병을 유발한다. 병원성 곰팡이는 항상 접촉에 의해 병을 유발시키는 것이 아니고, 감염 곰팡이의 종류, 숙주의 나이, 면역상태, 합병증 유무, 피부 건강도, 영양이나, 호르몬 상태에 따라 감염여부가 달리 나타난다. (Brasch, J. and Gottehaskamp, D. 1992. The effect of selected human steroid hormones upon the growth of dermatophytes with different adaptation to man. Mycopathologia 120(2); 87-92)Pathogenic fungi are distributed throughout the world and cause diseases in animals, including humans. The pathogenic fungus does not always cause disease by contact, but it varies depending on the type of infecting fungus, the age of host, immune status, complications, skin health, nutrition, and hormone status. (Brasch, J. and Gottehaskamp, D. 1992. The effect of selected human steroid hormones on the growth of dermatophytes with different adaptation to man. Mycopathologia 120 (2); 87-92)
대다수의 더마토파이트 속(Dermatophyte spp) 곰팡이에 의한 피부 및 그 부속기 감염을 피부 사상균증(윤선)이라고 한다. 이러한 곰팡이 그룹들은 표피 각화층에 국한되어 서싣하며, 일부 종들은 동물 조직 내에 침투하여 서식하기도 한다. 편의상 숙주에 따라, 엔트로필릭(Anthrophillic, 사람 기생), 주필릭(Zoophillic, 동물 기생), 지오필릭(토양내에 기생하는 saprophyte)라 한다. (Gupta, A.K., Einarson, T.R., Summerbell,R.C. and Shear, N.H. 1998. A North American perspective of Drug. 55(5): 645-674)Dermatophyte spp in the vast majority of the skin and its appendage infections caused by the fungus is called dermatophytosis. These fungi groups are localized to the epidermal keratinization layer, and some species invade and live in animal tissues. For convenience, it is called anthrophillic, zoophillic, and geophilic (saprophyte in the soil), depending on the host. (Gupta, A. K., Einarson, T. R., Summerbell, R. C. and Shear, N. H. 1998. A North American perspective of Drug. 55 (5): 645-674)
표재성 진균증의 치료는 원칙적으로 국소 및 전신의 항진균제 사용으로 이루어지며, 경우에 따라 각질 용해제의 도포를 병행하여 실시된다. 증상 및 피부병변이 소실된 후에도 약 2-4주간 치료가 요구된다. 그러나 족부백선의 경우, 환자의 부주의나 신체부위의 특성 및 면역 결핍성으로 인하여 치료에 실패하거나 재발할 가능성이 높다.Treatment of superficial mycoses is based on the use of topical and systemic antifungal agents and, in some cases, application of the keratolytic agent is carried out in parallel. After symptoms and skin lesions have disappeared, treatment for about 2-4 weeks is required. However, in the case of tinea pedis, it is highly likely that the patient will fail or recur due to the carelessness, the characteristics of the body part and the immunodeficiency.
지금까지 많은 항진균제들이 피부진균증을 치료하기 위해 이용되어 왔으나, 재발비율이 높고 피부독성에 대한 인식 증가로 인해 보다 안전하고 우수한 항진균 물질을 천연물에서 찾으려는 노력이 이루어지고 있다.So far, many antifungal agents have been used to treat skin fungi. However, due to the high recurrence rate and increased awareness of skin toxicity, efforts are being made to find safer and better fungicides in natural products.
본 발명은 진균에 대하여 항균활성을 가지는 식물정유를 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a plant essential oil having antimicrobial activity against fungi.
또한 본 발명은 백선균 또는 대장균에 대하여 항균 활성을 가지는 식물정유를 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a plant essential oil having antimicrobial activity against P. pseudomonas or E. coli.
또한 본 발명은 피부에 안정하며 우수한 항진균활성을 가지는 항피부진균증 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide an anti-dermatophyte composition which is stable to the skin and has excellent antifungal activity.
상기 목적을 달성하기 위해, 본 발명은 회향유, 계피유, 페파민트유로 이루어진 군으로부터 선택된 항균 조성물을 제공한다.In order to achieve the above object, the present invention provides an antimicrobial composition selected from the group consisting of fennel oil, cinnamon oil, and peppermint oil.
본 발명은 계피유, 회향유, 페파민트유를 이용하여 항균 조성물을 발명하였가. 상기 항균 조성물은 백선균 및 대장균에 대해 매우 강한 항균활성을 가지므로 독성이 없는 천연항균제로서 이용 가능성이 매우 높다.The present invention invented an antimicrobial composition using cinnamon oil, fennel oil, and peppermint oil. Since the antimicrobial composition has a very strong antimicrobial activity against Pseudomonas aeruginosa and Escherichia coli, it is very likely to be used as a natural antimicrobial agent having no toxicity.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 회향유, 계피유, 페파민트유가 항균 활성을 가짐을 확인하고 본 발명을 완성하였다.The present inventors have confirmed that fennel oil, cinnamon oil, and peppermint oil have antimicrobial activity and completed the present invention.
본 발명의 정유는 무좀을 유발하는 백선균 및 식중독을 유발하는 대장균에 적용하여 생육 저해환(Clear zone)을 측정한 결과 모두 우수한 항균 활성을 나타내었다.The essential oil of the present invention exhibited excellent antimicrobial activity as a result of measurement of clear zone of pycnogenesis causing athlete's foot and E. coli causing food poisoning.
본 발명은 식물정유를 포함하는 항균제 조성물을 제공한다. 상기 항균 조성물은 병원성 곰팡이 및 세균에 대하여 생육억제 활성을 가지는 것으로 바람직하게는 백선균 및 대장균에 대하여 생육억제 활성을 가진다.The present invention provides an antimicrobial composition comprising a plant essential oil. The antimicrobial composition has a growth inhibitory activity against pathogenic fungi and bacteria, and preferably has growth inhibitory activity against pycnotoxins and Escherichia coli.
본 발명의 항균 조성물은 표 1로 기제한 병원성 곰팡이 및 세균에 대하여 항균효과를 가진다. 대표적인 병원성 곰팡이는 트리코피톤 루프럼(Trichophyton rubrum, ATCC 28188)이고, 세균은 대장균(E.coli, ATCC 25922)이다.The antimicrobial composition of the present invention has an antimicrobial effect against pathogenic fungi and germs based on Table 1. A representative pathogenic fungus is Trichophyton rubrum (ATCC 28188), and the bacterium is E. coli (ATCC 25922).
본 발명의 항균 조성물은 병원성 곰팡이의 생육억제를 위한 용도로 사용할 수 있으며, 바람직하게는 세정제, 무좀 등의 피부진균증(derma-tomycosis) 치료제, 소독제 등으로 사용할 수 있다.The antimicrobial composition of the present invention can be used for inhibiting the growth of pathogenic fungi. Preferably, the antimicrobial composition of the present invention can be used as a treatment agent for skin fungus such as a detergent, athymosome, etc., as a disinfectant.
항피부진균증 조성물의 제제는 경고제, 과립제, 로션제, 리니멘트제(liniments), 리모나데제(limonades), 방향수제, 산제(散濟), 시럽제(syrups), 안연고제, 액제, 에어로솔제, 엑스제(extracts), 엘릭실제(elixier), 연고제가 바람직하나, 상기 제제에 한정되지 않는다.The formulation of the anti-dermatophyte composition may be selected from the group consisting of a warning agent, a granule, a lotion, a liniments, limonades, a handmade powder, a syrup, a syrups, an ointment, Extracts, elixirs and ointments are preferred, but not limited to these formulations.
항균 조성물은 제제 및 사용방법에 따라 생리약학적으로 허용 가능한 담체를 더욱 포함할 수 있으며, 항균 조성물 내 정유의 함량은 1 내지 20 중량 ％가 바람직하다. 항균 조성물의 투여량은 1일 10 내지 50 mg으로 1회 내지 3회 실시하는 것이 바람직하나, 병의 중한 정도 및 환자의 건강상태에 따라 조절하는 것이 더욱 바람직하다.The antimicrobial composition may further comprise a physiologically acceptable carrier depending on the preparation and method of use, and the content of the essential oil in the antimicrobial composition is preferably 1 to 20% by weight. The dosage of the antimicrobial composition is preferably 10 to 50 mg per day, preferably 1 to 3 times, more preferably in accordance with the severity of the disease and the health condition of the patient.
이하 본 발명의 실시예를 기재한다. 하기 실시예는 본 발명을 예시하기 위한 것일뿐 본 발명이 하기 실시예에 한정되는 것은 아니다.Hereinafter, examples of the present invention will be described. The following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
실시예 1 : 항균성 식물정유의 제조Example 1: Preparation of antimicrobial plant essential oil
미국의 버제사(Berje)로부터 회향유, 계피유, 페파민트유를 구입하였다.We purchased fennel oil, cinnamon oil, and peppermint oil from Berje, USA.
상기 정유는 증류법(steam dilstillation)으로 제조한 것이다. 소량의 증류수와 회향, 계피및 페파민트 각각을 믹서로 곱게 마쇄하여 3L 농축 플라스크에 넣었다. 가열멘틀(heating mentle)상에서 상기 플라스크의 멘틀 온도를 약 70로 하고, 디에틸에테르(diethyl ether)와 헥산이 각각 40ml(1/1, v/v)씩 담긴 플라스크의 멘틀 온도를 30-40(약 38)로 하여 2시간동안 가열하였다. 한번 증류하는데 필요한 시료의 양은 250g로 하고 추출 후 추출물내에 함유된 수분을 제거하기 위해 무수황산나트륨을 소량 넣은 다음 데시케이터(desiccator)에 방치하였고 이후 여지(Toyo No.2)에 걸러 농축하였다.The essential oil is prepared by steam dilillation. A small amount of distilled water, fennel, cinnamon and peppermint were each finely ground with a mixer and placed in a 3 L concentrated flask. The temperature of the mantle of the flask was adjusted to about 70 on a heating mentle and the temperature of the mantle of the flask containing 40 ml (1/1, v / v) of diethyl ether and hexane was adjusted to 30-40 About 38) for 2 hours. The amount of the sample required for one-time distillation was 250 g. To remove water contained in the extract, a small amount of anhydrous sodium sulfate was added and left in a desiccator. The mixture was filtered through a filter paper (Toyo No. 2) and concentrated.
실시예 2: 곰팡이 및 세균의 생육저해 활성Example 2: Inhibitory activity of growth of fungi and bacteria
하기 표 2는 식물정유에 대한 여지당 적정농도를 처리하였을 때, 백선균 1종과 대장균 1종에 대해 보이는 생육저해 활성을 측정하여 나타낸 것이다. 식물정유는 계피유:회향유:페파민트유를 혼합하였다.Table 2 shows the growth inhibitory activity of 1 pseudomonas sp. And 1 E. coli when the appropriate concentration of the plant essential oil was treated. Plant essential oil was mixed with cinnamon oil: fennel oil: peppermint oil.
식물정유에 의한 생육저해환의 크기가 10mm 이상으로 나타난 경우 곰팡이 및 세균에 생육저해활성을 가지는 것으로 판단하였다. 상기 표2에 제시된 바와 같이, 2종 모두 100mg과 50mg 처리시 항균활성을 나타내었다.Inhibition of plant growth by plant essential oil was more than 10 mm, and it was judged to have growth inhibitory activity against fungi and bacteria. As shown in Table 2 above, both of the antimicrobial activities were 100 mg and 50 mg, respectively.
실시예3 : 임상실험Example 3: Clinical trial
(1) 식물정유에 대한 임상실험(1) Clinical experiments on plant essential oils
상기 식물정유를 에탄올에 녹여 5％로 식물정유 조성물을 제조한 다음 족부가 감염된 5명의 성인 남성을 대상으로 임상실험을 하였다.The plant essential oil was dissolved in ethanol to prepare a plant essential oil composition with 5%, and clinical experiments were conducted on five male infected feet.
식물정유 조성물은 매일 3초 동안 1회 발에 분무하여(식물정유 성분이 0.1g 처리된 수준) 무좀균의 진전경과를 시간별로 조사하였다.The plant refinement composition was sprayed once per day for 3 seconds (level at which the plant essential oil component was treated at 0.1 g), and the evolution of the progress of athlete's foot was examined over time.
무좀이 심한 사람의 경우 사용 시간에 따라 하기의 양상이 나타났다.If athlete's foot is severe, the following pattern appears depending on the time of use.
1) 처리 1일 : 갈라지고 습진과 같이 진눌린 상피세포 또는 조직에서 진물이 사라졌다.1) Treatment Day 1: Cracks and eczema have disappeared from the crusted epithelial cells or tissues like eczema.
2) 처리 2일 : 갈라진 부위가 서서히 아물었다.2) Treatment 2 days: The cleavage site slowly bites.
3) 처리 3일 : 무좀 부위의 각질이 형성되고, 무좀 부위에서의 통증이 사라졌다.3) Treatment 3 days: The keratin of the athlete's foot area was formed, and the pain in the athlete's foot area disappeared.
4) 처리 4일 : 각질의 형성이 두드러져 완전히 치유된 양상을 보였다.4) Treatment 4 days: Formation of keratin was prominent and showed complete healing.
무좀이 심하지 않은 사람의 경우 1일 2회 처리로도 충분한 각질형성을 유도하여 무좀의 완치가 가능하였다.In the case of athlete's foot not severe, treatment of athlete's foot was possible by inducing sufficient keratinization twice a day.
또한 식물정유를 도포하는 기간 중에 환자의 피부에 별다른 병반 및 부작용이 관찰되지 않았다.In addition, no significant lesions and side effects were observed on the patient's skin during the application of the plant essential oil.
따라서, 식물정유 조성물은 무좀이 형성된 조직의 각질화를 야기시켜 생육조건의 변화를 가져오며, 무좀을 치료한다.Therefore, the plant refinement composition induces the keratinization of the tissue in which the athlete's foot is formed, thereby changing the growth conditions and treating the athlete's foot.
Claims (4)
항균 조성물은 백선균에 항균활성을 갖는 것인 항피부진균증 조성물.The method according to claim 1,
Wherein the antimicrobial composition has antimicrobial activity against Pseudomonas aeruginosa.
항균 조성물은 트리코피톤 루브럼(Trichophyton rubrum)인 진균에 대하여 항균활성을 갖는 것인 항피부진균증 조성물.The method according to claim 1,
Wherein the antimicrobial composition has an antimicrobial activity against fungi which are Trichophyton rubrum.
항균 조성물은 대장균(Escherichia coli)에 항균활성을 갖는 것인 항균 조성물.The method according to claim 1,
Wherein the antimicrobial composition has an antibacterial activity against Escherichia coli.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130132136A KR20150050906A (en) | 2013-11-01 | 2013-11-01 | Antibiotic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130132136A KR20150050906A (en) | 2013-11-01 | 2013-11-01 | Antibiotic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150050906A true KR20150050906A (en) | 2015-05-11 |
Family
ID=53388534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130132136A KR20150050906A (en) | 2013-11-01 | 2013-11-01 | Antibiotic composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150050906A (en) |
-
2013
- 2013-11-01 KR KR1020130132136A patent/KR20150050906A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6055905B2 (en) | Topical use of antimicrobial formulations | |
| US9775872B2 (en) | Topical pharmaceutical bases for preventing viral diseases | |
| JP6360267B2 (en) | Antifungal composition for the treatment of skin and nails | |
| KR20070092095A (en) | Disinfecting composition and methods of making and using same | |
| AU2010246847B2 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
| EA018425B1 (en) | Pharmaceutical, disinfectant or preservation extract of trigonella foenum-graecum, method for preparing and use thereof | |
| JP6415052B2 (en) | Pharmaceutical compositions comprising trans-cinnamaldehyde and their use in the treatment of infection | |
| US11771084B2 (en) | Preservation of personal care compositions | |
| JP2001524501A (en) | Antibacterial composition | |
| US20180000095A1 (en) | Microbicidal oil-in-water dispersion | |
| KR101281470B1 (en) | Compositions for skin external comprising castor oil extracted hexane, undecylenic acid, propyl alcohol, propylene glycol and water for prevention or treatment of tinea pedis | |
| US20200179473A1 (en) | Anti-pathogenic compositions | |
| US20120219640A1 (en) | Anti-infective solution for athlete's foot | |
| AU2013409215A1 (en) | Dermatological composition based on algae and olive leaf extracts | |
| US20150196520A1 (en) | Method and pharmaceutical composition for treating dermatophytosis | |
| KR20150050906A (en) | Antibiotic composition | |
| Ragab et al. | Antimicrobial effects of essential oils of Artemisia annua, Mentha longifolia, and Vitex agnus-castus and their nanoemulsions against pathogenic microbes causing cattle mastitis | |
| CN110772533A (en) | Multi-ion liquid for treating onychomycosis and preparation method and application thereof | |
| US9867775B2 (en) | Topical pharmaceutical bases for treating inflammatory disorders | |
| CN105326875B (en) | A kind of natural nonreactive moisturizing disinfectant liquid for skin and preparation method thereof | |
| US20140142177A1 (en) | Topical organic acid salt compositions suitable for treating infections | |
| AU2015101753A4 (en) | A naturally based preparation for the topical treatment and prevention of a broad spectrum of diseases in hoofed animals, and the promotion and maintenance of healthy growth of hooves. | |
| KR20100061091A (en) | A cleanser composition containing natural anti-bacterial components | |
| EP2637654A1 (en) | Topical organic acid salt compositions suitable for treating infections | |
| KR20220141724A (en) | Method for manufacturing of disinfectant composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |